Palvella Therapeutics, Inc.

What they do

Palvella develops product candidates based on its QTORIN platform, which is designed to deliver drugs into deep skin layers. Its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, is in clinical development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. A second candidate, QTORIN pitavastatin, is being developed for disseminated superficial actinic porokeratosis. The company became the public entity through a December 2024 merger with Pieris Pharmaceuticals.

Revenue drivers

• QTORIN rapamycin (microcystic LMs) — Lead program; no product revenue yet. Palvella has submitted the first module of a rolling NDA and plans a standalone U.S. commercial launch in the first half of 2027, if approved.
• QTORIN rapamycin (cutaneous VMs) — Phase 3 trial initiation planned for the fourth quarter of 2026; no revenue today. An FDA Breakthrough Therapy Designation request was not granted in July 2026 and the company plans to resubmit.
• QTORIN pitavastatin (DSAP) — Earlier-stage program for disseminated superficial actinic porokeratosis; a Phase 2 trial is planned for the second half of 2026. No revenue.
• Reported historical revenue — Company-reported annual revenue fell from $43.6M in 2019 to $25.9M in 2022 and was $42.8M in 2023; recent quarterly revenue was minimal ($53 thousand in Q1 2024, zero in Q2 and Q3 2024).

Recent performance

Reported annual revenue was $42.8M in 2023, but quarterly revenue was negligible in 2024 ($53 thousand in Q1 and zero in Q2 and Q3). Annual net income was $18.7M in 2023, then -$17.4M in 2024 and -$41.7M in 2025. Operating cash flow was -$10.8M in 2024 and -$25.0M in 2025. As of June 30, 2026, the company reported total assets of $253.5M, total liabilities of $36.6M, shareholder equity of $216.9M, and cash and equivalents of $187.8M.

Strategy

Palvella is prioritizing QTORIN rapamycin for microcystic LMs, having submitted the first module of a rolling NDA and targeting completion of the submission in the second half of 2026. It is preparing for a planned standalone U.S. commercial launch in the first half of 2027, if approved, and has recruited commercial and medical affairs leaders in rare disease and dermatology. The company plans to start a Phase 3 trial in cutaneous VMs in the fourth quarter of 2026 and a Phase 2 trial of QTORIN pitavastatin in DSAP in the second half of 2026. It also intends to generate additional candidates from the QTORIN platform for other rare skin diseases.

Risks

• No approved products or revenue — Palvella is clinical-stage with no FDA-approved therapies, and recent quarterly revenue has been negligible, so cash generation depends on future approvals.
• Regulatory and clinical uncertainty — The rolling NDA for QTORIN rapamycin in microcystic LMs is not complete, and the FDA declined a Breakthrough Therapy Designation for cutaneous VMs in July 2026, with a resubmission now planned.
• Cash burn — Net losses were $17.4M in 2024 and $41.7M in 2025, with operating cash use of $25.0M in 2025, funding development and pre-launch activities.
• Commercial launch execution — The planned standalone U.S. launch in the first half of 2027 depends on approval and on building commercial and medical affairs capabilities in rare disease and dermatology.

Outlook

Management expects to complete the rolling NDA submission for QTORIN rapamycin in microcystic LMs in the second half of 2026 and to launch the product in the first half of 2027, if approved. It also plans a Phase 3 trial in cutaneous VMs in the fourth quarter of 2026 and a Phase 2 trial of QTORIN pitavastatin in DSAP in the second half of 2026. Topline results from the Phase 2 LOTU trial in angiokeratomas are expected in the second half of 2027.